Ann: Response to media article, page-32

thanks @fielde

from AGM Q&A

Shareholder value question directed at Chairman – Qn: At time of 2018 AGM share price was $1.56. Today we are 35% below that. (now at 81.5c) This is in a period of 2 product launches which don’t appear to have produced significant revenue. Does the current executive team have the requisite commercial skills to turn the products into revenue success?

Chair answer – I’m not going to comment on the share price, I touched on it earlier.

Wow if he didnt want to comment then....

Do we have the skills? Advancing products through regulators is not easy

Mmmmmhh...

“The TGA has discussed the differences between a medicine and medical device with Starpharma verbally and in writing on several occasions, as recently as mid-January 2022. To date, Starpharma has not sought advice from the medicines authorisation branch of the TGA nor have they submitted an application for this product to be included in the [register] as a medicine.”

and Vivagel sales have been slowed in Europe due to pandemic. The Executive has approximately 100-120 years in the pharma industry so well positioned to advance the commercial side